GlassScriptPhysician profile
Jeffrey E Greenberg
NPI 1154363117
$9,095.85
in general payments reported to CMS, 2019-2025
63 companies · $3,558 in 2025
The $3,558 reported for 2025 was more than what 93% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $262 · 2020: $35.61 · 2021: $78.14 · 2022: $751 · 2023: $2,053 · 2024: $2,358 · 2025: $3,558.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,969.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,968.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $936.78 | 2022-2025 | Imfinzi, Enhertu, Lynparza |
| Janssen Biotech, INC. | $764.77 | 2022-2025 | Darzalex, Tecvayli, Rybrevant |
| Daiichi Sankyo INC. | $666.87 | 2023-2025 | Enhertu, Datroway, Vanflyta |
| Novartis Pharmaceuticals Corporation | $603.72 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $496.92 | 2021-2025 | Austedo Xr, Austedo, Austedo Xr |
| Merck Sharp & Dohme LLC | $482.34 | 2023-2025 | Keytruda, Welireg, Lynparza |
| Eisai INC. | $349.82 | 2023-2025 | |
| Novocure INC. | $337.45 | 2019-2024 | Optune |
| Bayer Healthcare Pharmaceuticals INC. | $330.12 | 2020-2025 | |
| Dendreon Pharmaceuticals LLC | $282.86 | 2024-2025 | Provenge |
| Genmab U.S., INC. | $203.75 | 2024-2025 | Epkinly |
| Pharmaessentia USA Corporation | $200.73 | 2023-2025 | Besremi |
| Incyte Corporation | $199.71 | 2022-2025 | Jakafi, Monjuvi |
| Jazz Pharmaceuticals INC. | $199.20 | 2023-2025 | |
| Pfizer INC. | $190.27 | 2024-2025 |
Show all 63 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $163.35 | 2022-2025 | Iclusig, Alunbrig, Ninlaro |
| Regeneron Healthcare Solutions, INC. | $148.10 | 2022-2025 | Libtayo, Lynozyfic |
| Genzyme Corporation | $129.69 | 2022-2025 | |
| Stemline Therapeutics INC. | $129.68 | 2023-2025 | Orserdu |
| Seagen INC. | $117.88 | 2022-2023 | Tukysa, Adcetris |
| Beigene USA, INC. | $115.53 | 2022-2024 | Brukinsa |
| E.R. Squibb & Sons, L.L.C. | $113.90 | 2022-2025 | Opdivo |
| Lilly USA, LLC | $108.01 | 2022-2025 | Verzenio, Jaypirca, Retevmo |
| Geron Corporation | $95.82 | 2025 | Rytelo |
| Aveo Pharmaceuticals, INC. | $92.36 | 2022-2025 | Fotivda |
| Emd Serono, INC. | $90.67 | 2022-2024 | Tepmetko, Bavencio |
| Astellas Pharma US INC | $81.83 | 2024-2025 | Xospata, Vyloy |
| Sobi, INC | $80.11 | 2023-2025 | |
| Mirati Therapeutics, INC. | $74.80 | 2023-2024 | Krazati |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.79 | 2024-2025 | Gilotrif |
| Celgene Corporation | $69.38 | 2022-2025 | Pomalyst, Reblozyl |
| Servier Pharmaceuticals LLC | $63.42 | 2023-2024 | |
| Puma Biotechnology, INC. | $62.48 | 2022-2025 | |
| Blueprint Medicines Corporation | $59.60 | 2022-2024 | Ayvakit |
| Rigel Pharmaceuticals, INC. | $58.41 | 2023 | Rezlidhia, Tavalisse |
| Abbvie INC. | $58.07 | 2025 | |
| Amgen INC. | $57.20 | 2022-2023 | Kyprolis, Blincyto |
| Alexion Pharmaceuticals, INC. | $55.84 | 2024 | Ultomiris |
| Glaxosmithkline, LLC. | $55.51 | 2023-2024 | Shingrix, Ojjaara |
| Ipsen Biopharmaceuticals, INC | $49.94 | 2023-2024 | Onivyde, Somatuline Depot |
| Taiho Oncology, INC. | $47.29 | 2025 | |
| Karyopharm Therapeutics INC. | $45.59 | 2023 | Xpovio |
| Exelixis INC. | $40.93 | 2022-2025 | Cabometyx |
| Kyowa Kirin, INC. | $40.01 | 2023-2025 | Poteligeo |
| Genentech USA, INC. | $39.36 | 2022-2023 | Phesgo |
| G1 Therapeutics, INC. | $37.66 | 2022-2023 | Cosela |
| Pharmacyclics LLC, An Abbvie Company | $37.55 | 2023 | Imbruvica, Epkinly |
| Apellis Pharmaceuticals, INC. | $36.37 | 2022-2023 | Empaveli |
| Caris Mpi, INC. | $34.11 | 2025 | Mi Cancer Seek |
| Corium, LLC | $32.73 | 2023 | Adlarity |
| Eusa Pharma (US) LLC | $27.49 | 2022 | |
| Cti Biopharma Corp. | $24.32 | 2023 | Vonjo |
| Legend Biotech USA INC. | $23.12 | 2024 | |
| Adaptive Biotechnologies Corporation | $22.42 | 2024 | Clonoseq |
| Ge Healthcare | $20.96 | 2022 | |
| Pharmacosmos Therapeutics INC. | $20.85 | 2024 | Cosela |
| Epizyme, INC. | $20.00 | 2022 | |
| Recordati_rare_diseases_inc. | $19.99 | 2023 | Sylvant |
| Myriad Genetic Laboratories, INC. | $17.21 | 2021 | |
| Adc Therapeutics America, INC. | $15.88 | 2022 | |
| Beone Medicines USA, INC. | $15.54 | 2025 | Tevimbra |
| Agios Pharmaceuticals, INC. | $13.83 | 2023 | Pyrukynd |
| Coherus Oncology, INC. | $12.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Greenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.